Innovus Pharma and Accelerize New Media Execs Show Commitment to Advancement
Wednesday, March 20, 2013
There are plenty of investors that follow the moves of others, whether it is that of an icon like Warren Buffett, a big hedge fund manager or even that of an insider buying stock or putting up cash of their own for funding. Whichever is followed, they all have merit, but in the OTC world, seeing an executive laying money from their own account on the line shows a strong commitment to the company and is perhaps a signal of things to come.
A couple thinly-traded stocks that have made moves in the past week or so that exemplify management’s efforts and dedication are Innovus Pharmaceuticals, Inc. (OTCBB:INNV) and Accelerize New Media, Inc. (OTCBB:ACLZ).
La Jolla, California-based Innovus said on Wednesday that it has its President and Chief Executive Officer, Dr. Bassam Damaj committed to provide additional funding to bring his total to $500,000 that he has supplied to the company. Damaj will deliver the funds only if Innovus has insufficient liquidity from other sources for payment of other obligations as it looks to grow its pipeline of products centered on respiratory, dermatology, autoimmune and sexual dysfunction products.
Copyright © 2013 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
More acutely, Innovus will be seeking to execute on binding term sheets that will add 10 new FDA-approved products to their portfolio, notably CIRCUMserum, a product for increasing sensitivity to the skin of the penis, expected to be especially beneficial to men with various conditions, including erectile dysfunction related to neuropathy of extremities. The company is also commercializing APEAZ, a topical solution for arthritis pain.
Damaj, formerly the CEO at Apricus Biosciences (Nasdaq:APRI) just assumed the position of chief executive at Innovus on January 22. Investors will be looking for Damaj’s influence to produce similar results as Apricus, where the company’s market capitalization grew from $17 million to $100 million during his time as top executive.
Innovus currently has a market capitalization of $7.29 million.
Accelerize’s chief executive, Brian Ross, has recently put his money where his mouth is through two purchases for an aggregate of 15,000 shares of ACLZ bought in the open market this month. The recent buys – on the 12th and 13th of March – up Ross’ stake to a little more than 15 percent of the company.
The purchases by the Accelerize chief certainly weren’t “bottom fishing” as Ross stepped in with the purchases as the stock price was making all-time highs, including a peak at $1.09 last Friday. They also came right after the Newport Beach, California-based provider of a proprietary Software as a Service platform for advertisers reported record revenue and profits for the full year 2012.
Accelerize is the owner/operator of Cake Marketing a solution for advertising companies to succinctly track and quantify performance of campaigns to better target consumers. Revenues from continuing operations for the full year mushroomed 146 percent from 2011 to a total of $5.8 million in 2012 as the company swung to a profit of $492,948 from a loss of $1.2 million in the year prior.
The moves have resulted in both companies having their “going concern” opinions removed from their regulatory filings, a big step for any developmental company and perhaps a bellwether for upcoming achievements.
Proper due diligence of the aforementioned companies is, as always, encouraged.
Other Penny Stock Movers
Hmmm...Approved Drug, Bristol Myers Squibb as Partner and Tiny Market Cap
Bonanza of a Deal Sends Bonanza Shares Skyward
Acasti Surges on Year-End Figures
Aurion Reports Progress on Finnish Mine